Cite
HARVARD Citation
Jimeno, A. et al. (n.d.). 191P Preliminary biomarker and safety results of SQZ-PBMC-HPV at RP2D in monotherapy and combination with checkpoint inhibitors in HLA A*02+ patients with recurrent, locally advanced, or metastatic HPV16+ solid tumors. Immuno-oncology technology. p. . [Online].